Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Corporate updatesFor media and investors only
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming Group to convene Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET.
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Corporate updatesPharming Group N.V. announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
Corporate updatesPharming Group N.V. announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Pharming Group announces the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST.
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
Corporate updatesPharming Group N.V. announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetable included in the CHMP Day 180 Second LoOI, and considering the CHMP’s decision to reschedule the Ad-Hoc Expert Group (AEG) meeting to the end of November, Pharming now expects the CHMP to issue its opinion on the leniolisib MAA in the first quarter of 2024.
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
Corporate updatesPharming Group N.V. announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.